Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,756.00
Bid: 1,753.00
Ask: 1,754.00
Change: -19.00 (-1.07%)
Spread: 1.00 (0.057%)
Open: 1,770.00
High: 1,770.00
Low: 1,740.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: CRH Leads FTSE 100 Winners, John Menzies Dives

Tue, 12th Nov 2013 12:32

LONDON (Alliance News) - The following stocks are the leading risers and fallers on the main London indices midday Tuesday.

-------

FTSE 100 - Winners

CRH is up 3.1%. The company said third-quarter like-for-like sales had increased by 2%, rebounding from the 6% reduction reported in its half-year results due to bad weather conditions. CRH said trading conditions improved across its international arms with positive trends in the US and Europe. Including the net impact of acquisitions, divestments and exchange rate movements, overall sales revenue of EUR5.4 billion for the quarter was 2% ahead of last year compared with a restated total of EUR5.3 billion in the 2012 period. Third quarter EBITDA was up 3% on 2012 despite what CRH called "adverse currency translation effects." The company said it expects second half EBITDA to be in line with last year.

Vodafone Group, up 1.5%, confirmed its full-year profit guidance as it said it swung to a pretax profit in the half year ended September 30. The mobile telecommunications giant swung to a pretax profit of GBP1.5 billion in the recent six months from a pretax loss of GBP3.9 billion in the same period the previous year. It posted revenue of GBP19.1 billion, up from GBP18.6 billion in the previous year. The company also raised its interim dividend and set out details for its Project Spring investment programme, originally announced when Vodafone sold its 45% interest in US joint venture Verizon Wireless for USD130 billion in September. Vodafone proposed an interim dividend of 3.53 pence each, up 8.0% from GBP3.37 pence, while stating its intention to pay a full-year dividend of 11 pence provided the disposal of its stake in Verizon Wireless is completed in the first quarter of 2014.

-------

FTSE 100 - Losers

Babcock International Group is down 1.3% despite reporting an increase in first half pretax profits of 32%. The company said its order book is stable and a good proportion of revenue for the next two years has already been contracted. However, the stock price has risen by about 10% over the last month. Investors had been pricing in an upgrade to earnings forecasts and have been disappointed this didn't happen, says Liberum Capital analyst Joe Brent. Moreover, the increase in the company's pension deficit is a negative. The deficit increased to GBP382 million from GBP261 million due to a 14% increase in the defined obligations, Brent explains.

GlaxoSmithKline, down 1%, said investigational heart disease treatment darapladib had not met its primary targets in a Phase III study. The company said the drug had failed to reduce occurrence of any major adverse cardiovascular event like stroke or heart attack in the study.

-------

FTSE 250 - Winners

Oxford Instruments jumps 13% after it said it is in talks to acquire AIM-listed Andor Technology PLC for 500 pence a share in cash, or GBP160 million. Oxford Instruments also reported a marked improvement in trading conditions in the second quarter that it expects to lift second-half results. The company said Andor is considering its offer. The two sides have been in talks since early July and Oxford Instruments has already raised its offer from an original proposal of 420 pence a share, and then a subsequent offer in September of 470 pence a share. Numis has upgraded Oxford Instruments to Buy from Add.

TalkTalk Telecom Group is up 11% after it raised its interim dividend and increased its full-year guidance on rising revenue in the half year ended September 30. The company said it now expects full-year revenue growth of at least 3%, having previously expected 2% growth. TalkTalk also is targeting a 25% earnings EBITDA margin by the full year 2017. The telecoms company proposed an interim dividend of 4.00 pence, up 16% from 3.45 pence in the previous year. The company saw revenue increase 1.8% to GBP843 million in the half, up from GBP828 million in the previous year.

Premier Farnell is up 6% after it said its sales trends improved in the third quarter of the year, driven by a strong performance from Asia Pacific and China, and strong sales growth in its industrial products division. It said that group sales per day rose by 3.3% in the third quarter ended November 3, with most of its divisions reporting improving trends in comparison to the first half of the year. The company said that group sales, excluding sales of Raspberry Pi, rose 2.1% year-on-year in the third quarter, from a 1.4% fall in the first half. Premier Farnell said that Asia Pacific delivered another strong sales performance in the quarter, up 11%, boosted by emerging markets such as China and India.

Workspace Group climbs 1.3%. The company has reported an increase in pretax profit for the first-half and raised its interim dividend by 10%. The real-estate investment trust also announced a London building acquisition. The company, which recently sold its mixed-use redevelopment in south London dubbed the "Biscuit Factory" for GBP51 million, posted pretax profit of GBP100.8 million for the period ended September 30, up from GBP24.6 million in 2012.

-------

FTSE 250 - Losers

John Menzies, off 7.1%, is the biggest faller on the index. The logistics group has issued a full-year profit warning, lowering its expectations for its struggling magazine and newspaper distribution arm. Distribution trading has remained tough in the third quarter, says Mike Murphy, an analyst at Numis. "Although magazine and newspaper volumes were in line with the decline in the first half, the returns from ancillary revenues and sticker collections was much weaker than expected." Alongside this, weaker-than-expected seasonal sales within the marketing services business also weighed on the company, Murphy adds. Subsequently, Numis has cut John Menzies to Hold from Add, lowering its target price to 774.00p from 834.00p.

Hunting is down 3.4% after it said that although overall trading had improved since the first half of its financial year, some businesses are still reporting mixed trading, with demand in Canada and Europe remaining subdued due to the rescheduling of drilling programmes in these regions.

Balfour Beatty, down 2.7%, has launched a GBP250 million convertible bond offering that it will use to pay off some short-term debt, a move that will further diversify its debt after its dollar-bond placing earlier in the year. The company said the senior, unsecured convertible bond will be due in 2018, and the underlying shares represent about 9.9% of its outstanding share issue. Balfour said it will use the proceeds to repay some of its revolving credit facility as well as for general corporate purposes.

Evraz falls 2.3% after it said it will start the first mass production of head-hardened rail lines in Russia after getting a license to do so. It said it will produce the rails mainly for Russian Railways, but it also expects to export some of the rails. Evraz claims its hardening process improves the durability of the rails substantially and reduces railway maintenance costs, as well as ensuring better safety and speed.

-------

AIM - Winners

Savile Group jumps 102%. Penna Consulting PLC said it has made a recommended GBP1.1 million cash takeover offer for the AIM-listed company, as it reported higher profits for the first half of its financial year despite a slight drop in revenue. In a joint statement, Penna and Savile said they had agreed a deal which will give Savile shareholders seven pence a share in cash, more than double Savile's closing share price of 3.25 pence Monday. Penna said it already has irrevocable undertakings to accept the offer from shareholders with 27.3% of Savile's outstanding shares.

Andor Technology is up 23% on the back of the news that FTSE 250-listed Oxford Instruments is in talks to acquire the company.

Sovereign Mines Of Africa leaps 11% after it said its Sovereign Mines of Guinea unit has won a new exploration concession that borders the south of its Mandiana-Magana gold concession in the country, a win it expects to significantly boost the gold strike at the site. The new concession covers an extension of a gold mineralisation area that forms the main part of its existing gold resource.

GW Pharmaceuticals is up 10% after it commenced a Phase 1b/2a clinical trial for the treatment of recurrent glioblastoma multiforme, meaning tumours that arise from the abnormal growth of the glial tissue of the brain. The company said that recurrent glioblastoma multiforme accounts for around 50% of new cases of brain cancer in the US each year.

Servicepower Technologies is up 6.3%. The company said it has demonstrated investment in its service scheduling product platform through implementation extensions to Germany, Czech Republic and Puerto Rico. It said the extensions support recent customer wins in these regions and expansion with existing customers.

-------

AIM - Losers

Cluff Natural Resources falls 19%. The company said it has conditionally raised GBP2 million in a share placing to develop its UK deep underground coal gasification portfolio. The investment company said it raised the money through a placing of 66.7 million shares at a price of 3.00 pence share, to new and existing institutional investors as well as a number of private investors. The placement will increase Cluff's total shares by 75% from 88.3 million currently.

James Cropper is down 11% after it posted a fall in pretax profit for the full year hit by green levies and input costs. The paper manufacturer said pretax profit declined to GBP216,000 for the period ended September 26, from GBP1.0 million a year earlier due to higher input costs that the firm was unable to pass through to customers and an increase in green levies.

-------

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2013 Alliance News Limited. All Rights Reserved.

More News
16 Apr 2024 09:17

GSK meningococcal vaccine accepted by US FDA for review

(Sharecast News) - GSK announced on Tuesday that its five-in-one meningococcal ABCWY (MenABCWY) vaccine candidate had been accepted for regulatory review by the US Food and Drug Administration (FDA).

Read more
16 Apr 2024 08:59

GSK's latest meningitis vaccine accepted for review by US regulator

(Alliance News) - GSK PLC on Tuesday said it has made progress in the development of its newest candidate, which combines the strengths of two other vaccines in its portfolio into one bacteria-fighting inoculation.

Read more
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more
9 Apr 2024 11:45

Pfizer RSV shot meets goals in trial of high-risk adults under age 60

April 9 (Reuters) - Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and generated an immune response in higher risk adults under the age of 60 similar to that in older adults, for whom the shot is already approved.

Read more
8 Apr 2024 09:13

LONDON BROKER RATINGS: Wizz Air raised; HSBC cuts Rentokil to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
4 Apr 2024 13:08

UK dividends calendar - next 7 days

Friday 5 April 
BBGI Global Infrastructure SAdividend payment date
Molten Ventures PLCdividend payment date
Pennon Group PLCdividend payment date
Real Estate Credit Investments Ltddividend payment date
Regional REIT Ltddividend payment date
Rights & Issues Investment Trust PLCdividend payment date
Sylvania Platinum Ltddividend payment date
Titon Holdings PLCdividend payment date
Triple Point Energy Transition PLCdividend payment date
Monday 8 April 
Alumasc Group PLCdividend payment date
LondonMetric Property PLCdividend payment date
Redrow PLCdividend payment date
Tuesday 9 April 
CT Global Managed Portfolio Trust PLCdividend payment date
Downing Strategic Micro-Cap Investment Trust PLCdividend payment date
Dunelm Group PLCspecial dividend payment date
Hays PLCdividend payment date
Renishaw PLCdividend payment date
Safestore Holdings PLCdividend payment date
Wednesday 10 April 
Assura PLCdividend payment date
Primorus Investments PLCspecial dividend payment date
Wilmington PLCdividend payment date
Thursday 11 April 
Amedeo Air Four Plus Ltdex-dividend payment date
Athelney Trust PLCdividend payment date
Aviva PLCex-dividend payment date
Balanced Commercial Property Trust Ltdex-dividend payment date
Barratt Developments PLCex-dividend payment date
Begbies Traynor Group PLCex-dividend payment date
Bioventix PLCex-dividend payment date
Blackfinch Spring VCT PLCex-dividend payment date
BlackRock Latin American Investment Trust PLCex-dividend payment date
Caledonia Mining Corpex-dividend payment date
Capital & Regional PLCex-dividend payment date
Chesnara PLCex-dividend payment date
Colefax Group PLCdividend payment date
CT Private Equity Trust PLCex-dividend payment date
Downing Strategic Micro-Cap Investements Trust PLCex-dividend payment date
Driver Group PLCdividend payment date
F&C Investment Trust PLCex-dividend payment date
Foxtons Group PLCex-dividend payment date
Grafton Group PLCex-dividend payment date
GSK PLCdividend payment date
Harbour Energy PLCex-dividend payment date
Hargreaves Services PLCdividend payment date
Howden Joinery Group PLCex-dividend payment date
Hunting PLCex-dividend payment date
i3 Energy PLCex-dividend payment date
International Personal Finance PLCex-dividend payment date
International Public Partnerships Ltdex-dividend payment date
ITV PLCex-dividend payment date
Johnson Service Group PLCex-dividend payment date
JPMorgan Asia Growth & Income PLCex-dividend payment date
JPMorgan Japan Small Cap Growth & Income PLCex-dividend payment date
Just Group PLCex-dividend payment date
Kenmare Resources PLCex-dividend payment date
Kerry Group PLCex-dividend payment date
Kings Arms Yard VCT PLCex-dividend payment date
Law Debenture Corp PLCdividend payment date
Lloyds Banking Group PLCex-dividend payment date
Lowland Investment Cos PLCex-dividend payment date
Luceco PLCex-dividend payment date
Man Group PLCex-dividend payment date
Manchester & London Investement Trust PLCex-dividend payment date
Marble Point Loan Financing Ltdex-dividend payment date
Mercantile Investment Trust PLCex-dividend payment date
Mobius Investment Trust PLCex-dividend payment date
MTI Wireless Edge Ltddividend payment date
North American Income Trust PLCex-dividend payment date
Northamber PLCex-dividend payment date
Octopus Apollo VCT PLCex-dividend payment date
Phoenix Group Holdings PLCex-dividend payment date
Reckitt Benckiser Group PLCex-dividend payment date
Ricardo PLCdividend payment date
Savills PLCex-dividend payment date
Schroder Asian Total Return Investment Cos PLCex-dividend payment date
Schroder European Real Estate Investment Trust PLCex-dividend payment date
Scottish American Investment Cos PLCdividend payment date
Smurfit Kappa Group PLCex-dividend payment date
Softcat PLCex-dividend payment date
Somero Enterprises Incex-dividend payment date
Supermarket Income REIT PLCex-dividend payment date
Synectics PLCex-dividend payment date
TP ICAP Group PLCex-dividend payment date
Trifast PLCdividend payment date
TT Electronics PLCex-dividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.